custom-designed exon-targeted array comparative genomic hybridization (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
custom-designed exon-targeted array comparative genomic hybridization
Custom Designed Exon Targeted Array Comparative Genomic Hybridization, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom-designed+exon-targeted+array+comparative+genomic+hybridization/pm30322717-60-7-11
Average 90 stars, based on 1 article reviews
Custom Designed Exon Targeted Array Comparative Genomic Hybridization, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/custom-designed+exon-targeted+array+comparative+genomic+hybridization/pm30322717-60-7-11
Average 90 stars, based on 1 article reviews
custom-designed exon-targeted array comparative genomic hybridization - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Hybridization:Article Title: Germline pathogenic variants identified in women with ovarian tumors. Article Snippet: Article history: Received 6 June 2018 Received in revised form 25 September 2018 Accepted 28 September 2018 Available online xxxx Objective.. The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options available to providers and patients.. We report the frequency of pathogenic variants identified among individuals with ovarian cancer undergoing clinical genetic testing via a multi-gene hereditary cancer panel. Ligation:Article Title: Germline pathogenic variants identified in women with ovarian tumors. Article Snippet: Article history: Received 6 June 2018 Received in revised form 25 September 2018 Accepted 28 September 2018 Available online xxxx Objective.. The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options available to providers and patients.. We report the frequency of pathogenic variants identified among individuals with ovarian cancer undergoing clinical genetic testing via a multi-gene hereditary cancer panel. Amplification:Article Title: Germline pathogenic variants identified in women with ovarian tumors. Article Snippet: Article history: Received 6 June 2018 Received in revised form 25 September 2018 Accepted 28 September 2018 Available online xxxx Objective.. The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options available to providers and patients.. We report the frequency of pathogenic variants identified among individuals with ovarian cancer undergoing clinical genetic testing via a multi-gene hereditary cancer panel. Multiplex Ligation-dependent Probe Amplification:Article Title: Germline pathogenic variants identified in women with ovarian tumors. Article Snippet: Article history: Received 6 June 2018 Received in revised form 25 September 2018 Accepted 28 September 2018 Available online xxxx Objective.. The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options available to providers and patients.. We report the frequency of pathogenic variants identified among individuals with ovarian cancer undergoing clinical genetic testing via a multi-gene hereditary cancer panel. Microarray:Article Title: Germline pathogenic variants identified in women with ovarian tumors. Article Snippet: Article history: Received 6 June 2018 Received in revised form 25 September 2018 Accepted 28 September 2018 Available online xxxx Objective.. The recognition of genes implicated in ovarian cancer risk beyond BRCA1, BRCA2, and the Lynch syndrome genes has increased the variety of testing options available to providers and patients.. We report the frequency of pathogenic variants identified among individuals with ovarian cancer undergoing clinical genetic testing via a multi-gene hereditary cancer panel. |